Epiomic Epidemiology Series: Tuberculosis Forecast in 11 Major Markets 2015-2025

October 2015 | 52 pages | ID: EEF1E677D45EN
Black Swan Analysis limited

Abstracts

Tuberculosis (TB) is a chronic bacterial infection caused by variants of Mycobacterium tuberculosis. Usually affecting the lungs as the primary site of infection, but can affect extra-pulmonary sites also. Transmission occurs by an infected person with active TB, coughing, sneezing or even talking to other people. Droplets of saliva or mucus enter the air and other people are able to inhale the mycobacterium within the droplets.

This report provides the current incidence population for TB across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Poland and Romania) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of TB patient origin status, drug resistance and causative species of TB. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of TB have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for TB include:

• HIV/AIDS
• Diabetes
• Bloody sputum
• Bone pain

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global TB’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of TB and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on TB’s prevalent population.
• Examination of the incidence of the different causative species for TB.
• Identify sub-populations within TB which require treatment.
• Gain an understanding of the specific markets that have the largest number of TB patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/ Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Incidence for Tuberculosis
Features of Tuberculosis
  Classification of Tuberculosis
  Tuberculosis Location
  Tuberculosis-Causing Species
  Origin Status of Patients with Tuberculosis
Tuberculosis Case Type
  Treatment Outcome of Tuberculosis Case Type
Associated Conditions of Tuberculosis
  HIV
  Tuberculosis Drug Resistance
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

Incidence of Tuberculosis, total (000s)
Incidence of Tuberculosis, males (000s)
Incidence of Tuberculosis, females (000s)
Diagnosis classification of Tuberculosis, total (000s)
Site affected by Tuberculosis, total (000s)
Mycobacterium species causing Tuberculosis, total (000s)
Origin status of patients with Tuberculosis, total (000s)
Case type of patients with Tuberculosis, total (000s)
Treatment outcome of new cases of Tuberculosis, total (000s)
Treatment outcome of previously treated cases of Tuberculosis, total (000s)
HIV in patients with Tuberculosis, total (000s)
Miliary Tuberculosis in Tuberculosis patients with HIV, total (000s)
Multi-drug resistance in patients with Tuberculosis, total (000s)
Any Tuberculosis drug resistance in patients with Tuberculosis, total (000s)
Isoniazid resistance in patients with Tuberculosis, total (000s)
Abbreviations and Acronyms used in the report
USA Incidence of Tuberculosis by 5-yr age cohort, males (000s)
USA Incidence of Tuberculosis by 5-yr age cohort, females (000s)
France Incidence of Tuberculosis by 5-yr age cohort, males (000s)
France Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Germany Incidence of Tuberculosis by 5-yr age cohort, males (000s)
Germany Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Italy Incidence of Tuberculosis by 5-yr age cohort, males (000s)
Italy Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Spain Incidence of Tuberculosis by 5-yr age cohort, males (000s)
Spain Incidence of Tuberculosis by 5-yr age cohort, females (000s)
United Kingdom Incidence of Tuberculosis by 5-yr age cohort, males (000s)
United Kingdom Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Brazil Incidence of Tuberculosis by 5-yr age cohort, males (000s)
Brazil Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Japan Incidence of Tuberculosis by 5-yr age cohort, males (000s)
Japan Incidence of Tuberculosis by 5-yr age cohort, females (000s)
India Incidence of Tuberculosis by 5-yr age cohort, males (000s)
India Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Poland Incidence of Tuberculosis by 5-yr age cohort, males (000s)
Poland Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Romania Incidence of Tuberculosis by 5-yr age cohort, males (000s)
Romania Incidence of Tuberculosis by 5-yr age cohort, females (000s)